LYMPHOMA, MANTLE-CELL
Clinical trials for LYMPHOMA, MANTLE-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, MANTLE-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, MANTLE-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat leukemia and lymphoma
Disease control CompletedThis phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising combo targets tough lymphoma in seniors
Disease control CompletedThis study tested whether adding the targeted drug venetoclax to standard chemotherapy (R-BAC) helps older patients with high-risk mantle cell lymphoma. 141 patients received the combination, aiming to improve how long they stay cancer-free. The approach is designed for those who…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of ibrutinib and rituximab against other standard drug pairs in 36 people with mantle cell lymphoma that had returned or stopped responding to treatment. The main goal was to check safety and side effects, and to keep giving the treatment to those …
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC